title: The effects of leptin in combination with a cannabinoid receptor 1 antagonist, AM 251, or cannabidiol on food intake and body weight in rats fed a high-fat or a free-choice high sugar diet.
abstract: High intake of fats and sugars has prompted a rapid growth in the number of obese individuals worldwide. To further investigate whether simultaneous pharmacological intervention in the leptin and cannabinoid system might change food and water intake, preferences for palatable foods, and body weight, we have examined the effects of concomitant intraperitoneal administration of leptin and AM 251, a cannabinoid 1 (CB1) receptor antagonist, or cannabidiol (CBD), a plant cannabinoid, in rats maintained on either a high-fat (HF) diet (45% energy from fat) or free-choice (FC) diet consisting of high-sucrose and normal rat chow (83% and 61% energy from carbohydrates, respectively). Leptin at a dose of 100 μg/kg injected individually for 3 subsequent days to rats fed a HF diet reduced significantly the daily caloric intake and inhibited body weight gain. The hormone had no significant effects, however, on either caloric intake, body weight or food preferences in rats fed an FC diet. Co-injection of leptin and 1 mg/kg AM 251 resulted in a further significant decrease in HF diet intake and a profound reduction in body weight gain both in HF diet- and FC diet-fed rats. This drug combination, however, had no effect on the consumption of high-sucrose chow. In contrast, 3mg/kg of CBD co-injected with leptin did not modify leptin effects on food intake in rats maintained on an FC or HF diet. None of the drug combinations affected water consumption. It is concluded that the concomitant treatment with leptin and AM 251 attenuated markedly body weight gain in rats maintained on high-calorie diets rich in fat and carbohydrates but did not affect preferences for sweet food.
authors.affiliation: Department of Behavioral Pathophysiology, Institute of General and Experimental Pathology, Medical University of Lodz, Poland. magdalena.wierucka@stud.umed.lodz.pl.
authors.forename: M
authors.initials: M
authors.lastname: Wierucka-Rybak
authors.forename: M
authors.initials: M
authors.lastname: Wolak
authors.forename: E
authors.initials: E
authors.lastname: Bojanowska
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002185:Cannabidiol / Q000008:administration & dosage*; D063387:Cannabinoid Receptor Antagonists / Q000008:administration & dosage*; D059305:Diet, High-Fat; D019422:Dietary Sucrose / Q000008:administration & dosage*; D004338:Drug Combinations; D004435:Eating / Q000187:drug effects; D020738:Leptin / Q000008:administration & dosage*; D008297:Male; D010880:Piperidines / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage*; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors
chemical_list: D063387:Cannabinoid Receptor Antagonists; D019422:Dietary Sucrose; D004338:Drug Combinations; D020738:Leptin; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D002185:Cannabidiol; C103505:AM 251